TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation

Journal of Immunotherapy

Volumn 37, Issue 8, 2014, Pages 416-425

  Ahmed, Raija K ^a   Poiret, Thomas ^b   Ambati, Aditya ^b   Rane, Lalit ^b   Remberger, Mats ^b   Omazic, Birgitta ^b   Vudattu, Nalini K ^c   Winiarski, Jacek ^b   Ernberg, Ingemar ^b   Axelsson Robertson, Rebecca ^b   Magalhaes, Isabelle ^b   Castelli, Chiara ^d   Ringden, Olle ^b   Maeurer, Markus ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c YALE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

aHSCT; DN T cells; EBV; Immune reconstitution; Retroviral TCR transfer; T cells; Tetramer

Indexed keywords

HLA A2 ANTIGEN; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; T LYMPHOCYTE RECEPTOR; CD4 ANTIGEN; CD8 ANTIGEN; HLA A24 ANTIGEN; HLA-A*02:01 ANTIGEN; HLA-A*24:02 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTOME; VIRUS ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; ADOLESCENT; ALLOTRANSPLANTATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; JURKAT CELL LINE; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HUMANS; INTERLEUKIN-8; JURKAT CELLS; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSCRIPTOME; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84925817381     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000047     Document Type: Article

References (46)

1. Rasche L, Kapp M, Einsele H, et al. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013; 49: 163-167.
2. Zhang ZX, Yang L, Young KJ, et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000; 6: 782-789.
3. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol. 2012; 4: 48-58.
4. Cowley SC, Hamilton E, Frelinger JA, et al. CD4-CD8-T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med. 2005; 202: 309-319.
5. Cowley SC, Meierovics AI, Frelinger JA, et al. Lung CD4-CD8-double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol. 2010; 184: 5791-5801.
6. Fischer K, Voelkl S, Heymann J, et al. Isolation and characterization of human antigen-specific TCR alpha beta + CD4(-)CD8-double-negative regulatory T cells. Blood. 2005; 105: 2828-2835.
7. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008; 181: 8761-8766.
8. McIver Z, Serio B, Dunbar A, et al. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2008; 141: 170-178.
9. Ye H, Chang Y, Zhao X, et al. Characterization of CD3 + CD4-CD8 - (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation. Transpl Immunol. 2011; 25: 180-186.
10. Dowdell KC, Niemela JE, Price S, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 2010; 115: 5164-5169.
11. Russell TB, Kurre P. Double-negative T cells are non-ALPS-specific markers of immune dysregulation found in patients with aplastic anemia. Blood. 2010; 116: 5072-5073.
12. Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2013; 99: 346-352.
13. Young KJ, Kay LS, Phillips MJ, et al. Antitumor activity mediated by double-negative T cells. Cancer Res. 2003; 63: 8014-8021.
14. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J. 2002; 8: 2-11.
15. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. 2003; 31: 253-261.
16. Ringden O, Karlsson H, Olsson R, et al. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009; 147: 614-633.
17. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994; 83: 2723-2730.
18. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989; 73: 1729-1734.
19. Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004; 78: 122-127.
20. Mattsson J, Uzunel M, Remberger M, et al. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2001; 71: 433-439.
21. Magalhaes I, Vudattu NK, Ahmed RK, et al. High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology. 2010; 131: 128-140.
22. Perez-Bercoff L, Vudattu NK, Byrareddy SN, et al. Reduced IL-7 responsiveness defined by signal transducer and activator of transcription 5 phosphorylation in T cells may be a marker for increased risk of developing cytomegalovirus disease in patients after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant. 2014; 128-132.
23. Omar H, Ahmed R, Rane L, et al. Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT. J Immunother. 2011; 34: 390-396.
24. Jager E, Maeurer M, Hohn H, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer. 2000; 86: 538-547.
25. Jager E, Hohn H, Necker A, et al. Peptide-specific CD8 + T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer. 2002; 98: 376-388.
26. Saito T, Weiss A, Miller J, et al. Specific antigen-Ia activation of transfected human T cells expressing murine Ti alpha betahuman T3 receptor complexes. Nature. 1987; 325: 125-130.
27. Maeurer MJ, Martin DM, Storkus WJ, et al. TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol Today. 1995; 16: 603-604.
28. Maeurer MJ, Hurd S, Martin DM, et al. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am. 1995; 1: 162-170.
29. Maeurer MJ, Gollin SM, Martin D, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immuno-dominant MART-1/Melan-A antigen. J Clin Invest. 1996; 98: 1633-1641.
30. Bodinier M, Peyrat MA, Tournay C, et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med. 2000; 6: 707-710.
31. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med. 1995; 181: 363-368.
32. Jager E, Hohn H, Karbach J, et al. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. Int J Cancer. 1999; 81: 979-984.
33. Anand A, Dean GS, Quereshi K, et al. Characterization of CD3 + CD4-CD8 - (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus. 2002; 11: 493-500.
34. Huang MC, Patel K, Taub DD, et al. Human CD4-8-T cells are a distinctive immunoregulatory subset. FASEB J. 2010; 24: 2558-2566.
35. Bernardo I, Mancebo E, Aguilo I, et al. Phenotypic and functional evaluation of CD3 + CD4-CD8-T cells in human CD8 immunodeficiency. Haematologica. 2011; 96: 1195-1203.
36. Caristi S, Piraino G, Cucinotta M, et al. Prostaglandin E2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes. J Biol Chem. 2005; 280: 14433-14442.
37. Bleesing JJ, Brown MR, Novicio C, et al. A composite picture of TcR alpha/beta(+) CD4(-)CD8(-) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol. 2002; 104: 21-30.
38. Krishnan S, Farber DL, Tsokos GC. T cell rewiring in differentiation and disease. J Immunol. 2003; 171: 3325-3331.
39. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993; 53: 5613-5616.
40. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992; 258: 1795-1798.
41. Seitzer U, Kayser K, Hohn H, et al. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology. 2001; 104: 269-277.
42. Mixter PF, Russell JQ, Morrissette GJ, et al. A model for the origin of TCR-alphabeta+ CD4-CD8-B220+ cells based on high affinity TCR signals. J Immunol. 1999; 162: 5747-5756.
43. Mehal WZ, Crispe IN. TCR ligation on CD8+ T cells creates double-negative cells in vivo. J Immunol. 1998; 161: 1686-1693.
44. Trimble LA, Kam LW, Friedman RS, et al. CD3zeta and CD28 down-modulation on CD8 T cells during viral infection. Blood. 2000; 96: 1021-1029.
45. Pitcher LA, Mathis MA, Subramanian S, et al. Selective expression of the 21-kilodalton tyrosine-phosphorylated form of TCR zeta promotes the emergence of T cells with autoreactive potential. J Immunol. 2005; 174: 6071-6079.
46. Rosenberg SA Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol. 2011; 8: 577-585.